Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.

Growth hormone releasing peptides (GHRPs) stimulate secretion of endogenous growth hormone and are listed on the World Anti-Doping Agency (WADA) Prohibited List. To develop an effective method for GHRPs anti-doping control we have investigated metabolites of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin in urine after nasal administration. Each compound was administrated to one volunteer. Samples were collected for 2 days after administration, processed by solid-phase extraction on weak cation exchange cartridges and analyzed by means of nano-liquid chromatography - high resolution mass spectrometry. Six metabolites of GHRP-1 were identified. GHRP-1 in the parent form was not detected. GHRP-1 (2-4) free acid was detected in urine up to 27 h. GHRP-2, GHRP-2 free acid and GHRP-2 (1-3) free acid were detected in urine up to 47 h after administration. GHRP-6 was mostly excreted unchanged and detected in urine 23 h after administration, its metabolites were detectable for 12 h only. Hexarelin and Ipamorelin metabolized intensively and were excreted as a set of parent compounds with metabolites. Hexarelin (1-3) free acid and Ipamorelin (1-4) free acid were detected in urine samples after complete withdrawal of parent substances. GHRPs and their most prominent metabolites were included into routine ultra-pressure liquid chromatography-tandem mass spectrometry procedure. The method was fully validated, calibration curves of targeted analytes were obtained and excretion curves of GHRPs and their metabolites were plotted. Our results confirm that the detection window after GHRPs administration depends on individual metabolism, drug preparation form and the way of administration.

[1]  Grigory Rodchenkov,et al.  Anti-doping analyses at the Sochi Olympic and Paralympic Games 2014. , 2014, Drug testing and analysis.

[2]  J. Vine,et al.  A high-throughput LC-MS/MS screen for GHRP in equine and human urine, featuring peptide derivatization for improved chromatography. , 2014, Drug testing and analysis.

[3]  V. Besada,et al.  Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  M. Thevis,et al.  Metabolism of growth hormone releasing peptides. , 2012, Analytical chemistry.

[5]  M. Thevis,et al.  Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry , 2011, Analytical and bioanalytical chemistry.

[6]  S. Kageyama,et al.  Influence of intravenous administration of growth hormone releasing peptide-2 (GHRP-2) on detection of growth hormone doping: growth hormone isoform profiles in Japanese male subjects. , 2010, Drug testing and analysis.

[7]  S. Kageyama,et al.  Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry. , 2010, Rapid communications in mass spectrometry : RCM.

[8]  L. Anderson,et al.  Physiology of ghrelin and related peptides. , 2005, Domestic animal endocrinology.

[9]  E. Arvat,et al.  Effects of GHRP-2 and Hexarelin, Two Synthetic GH-Releasing Peptides, on GH, Prolactin, ACTH and Cortisol Levels in Man. Comparison with the Effects of GHRH, TRH and hCRH , 1997, Peptides.

[10]  T. Badger,et al.  Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. , 1997, The Journal of endocrinology.

[11]  V. Lenaerts,et al.  Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. , 1994, The Journal of clinical endocrinology and metabolism.

[12]  Y. Okimura,et al.  Intranasal administration of His-D-Trp-Ala-Trp-D-Phe-LysNH2 (growth hormone releasing peptide) increased plasma growth hormone and insulin-like growth factor-I levels in normal men. , 1991, Endocrinologia japonica.

[13]  J. Segura,et al.  Growth hormone secretagogues: out of competition , 2011, Analytical and Bioanalytical Chemistry.

[14]  Johansen Nl,et al.  Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption , 1998 .